MedAvail (MDVLQ) 10-K 27 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Mar. 23, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	MYOS Corp
Entity Central Index Key	1402479
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$35.80
Entity Common Stock, Shares Outstanding		3,103,300

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash	$1,567	$451
Accounts receivable, net	982	645
Inventories, net	1,814	143
Prepaid expenses and other current assets	745	215
Total current assets	5,108	1,454
Fixed assets, net of accumulated depreciation	313	344
Intangible assets, net of accumulated amortization	1,990	2,038
Total assets	7,411	3,836
Current liabilities:
Accounts payable	79	184
Accrued expenses	495	312
Total current liabilities	574	496
Contract liability	101
Total liabilities	675	496
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 500,000 shares authorized; no shares issued and outstanding
Common stock, $.001 par value; 8,000,000 and 6,000,000 authorized at December 31, 2014 and 2013, respectively; 3,103,300 and 2,227,447 shares issued and outstanding at December 31, 2014 and 2013, respectively	3	2
Additional paid-in capital	25,100	17,246
Accumulated deficit	-18,367	-13,908
Total stockholders' equity	6,736	3,340
Total liabilities and stockholders' equity	$7,411	$3,836

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Balance Sheets [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	8,000,000	6,000,000
Common stock, shares issued	3,103,300	2,227,447
Common stock, shares outstanding	3,103,300	2,227,447

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Statements of Operations [Abstract]
Net sales	$3,343	$3,318
Cost of sales (excludes amortization of acquired intangibles)	1,420	1,521
Gross profit	1,923	1,797
Operating expenses
Research and development	1,348	754
Selling, general and administrative	5,621	5,310
Amortization	154
Loss on asset impairment	5
Total operating expenses	7,128	6,064
Operating loss	-5,205	-4,267
Other income (expense):
Interest income	2	4
Interest expense	-4
Total other income (expense)	-2	4
Loss before income taxes	-5,207	-4,263
Income tax benefit	748
Net loss and comprehensive loss	($4,459)	($4,263)
Net loss per share attributable to common shareholders:
Basic and diluted	($1.56)	($1.93)
Weighted average number of common shares outstanding:
Basic and diluted	2,853	2,213

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Stockholders' Equity (USD $)	Total	Common Stock	Additional paid-in capital	Accumulated deficit
In Thousands, except Share data
Beginning Balance at Dec. 31, 2012	$6,198	$2	$15,841	($9,645)
Beginning Balance, shares at Dec. 31, 2012		2,200,667
Shares issued to employee
Shares issued to employee, shares		20
Shares issued for services	70		70
Shares issued for services, shares		26,760
Stock-based compensation expense	1,335		1,335
Net loss	-4,263			-4,263
Ending Balance at Dec. 31, 2013	3,340	2	17,246	-13,908
Ending Balance, shares at Dec. 31, 2013		2,227,447
Proceeds from issuance of common stock, net	6,234	1	6,233
Proceeds from issuance of common stock, net, shares		825,211
Shares issued for private placement fee
Shares issued for private placement fee, shares		47,351
Additional shares issued for odd lots in connection with reverse stock split
Additional shares issued for odd lots in connection with reverse stock split, shares		91
Shares issued to directors
Shares issued to directors, shares		7,000
Shares issued to employee
Shares issued to employee, shares		200
Shares issued for services
Shares issued for services, shares		6,000
Forfeiture of shares issued for services	-70		-70
Forfeiture of shares issued for services, shares		-10,000
Stock-based compensation expense	1,691		1,691
Net loss	-4,459			-4,459
Ending Balance at Dec. 31, 2014	$6,736	$3	$25,100	($18,367)
Ending Balance, shares at Dec. 31, 2014		3,103,300

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flow (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net loss	($4,459)	($4,263)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	49	37
Amortization	155
Provision for inventory reserve	328
Bad debt expense	390
Stock-based compensation	1,691	1,335
Derivative charges and credits		28
Impairment charge	5
Changes in operating assets and liabilities:
(Increase) in accounts receivable	-727	-443
(Increase) decrease in inventories	-1,999	76
(Increase) decrease in prepaid expenses and other assets	-600	-61
Increase (decrease) in accounts payable and accrued expenses	78	137
Net cash used in operating activities	-5,089	-3,154
Cash Flows From Investing Activities:
Additions to fixed assets	-23	-373
Acquisition of intangible assets	-6	-2
Net cash used in investing activities	-29	-375
Cash Flows From Financing Activities:
Proceeds from issuance of common stock	6,234
Offering costs	-317
Net cash provided by financing activities	6,234
Net increase (decrease) in cash	1,116	-3,529
Cash at beginning of period	451	3,980
Cash at end of period	1,567	451
Cash paid during the year for:
Interest	4
Income taxes, net of refunds	2	2
Supplemental schedule of non-cash investing and financing activities:
Warrants issued with common stock	4,973
Patent acquired in exchange for royalties obligation	101
Forfeiture of restricted stock for prepaid consulting services	-70
Stock issued for prepaid consulting services		70
Conversion of derivative liability to accrued expense		$150

Nature_of_Operations_Basis_of_

Nature of Operations, Basis of Presentation and Liquidity	12 Months Ended
	Dec. 31, 2014
Nature of Operations, Basis of Presentation and Liquidity [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY
	Nature of Operations
	MYOS Corporation is an emerging bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function. The Company was incorporated under the laws of the State of Nevada on April 11, 2007. As used in this report, the terms the “Company”, “MYOS”, “our”, or “we”, refer to MYOS Corporation, its predecessor, Atlas Therapeutics Corporation, and subsidiary, unless the context indicates otherwise. On February 25, 2011, the Company entered into an agreement to acquire the intellectual property for Fortetropin®, our platform dietary supplement product from Peak Wellness, Inc. (the "Acquisition"). Since the Acquisition, the Company’s principal business activities have been focused on deepening our scientific understanding of the activity of Fortetropin and to leverage this knowledge to strengthen and build our intellectual property; developing sales and marketing strategies aimed at expanding our commercial presence in the sports nutrition and age management markets; evaluating the value of Fortetropin in therapeutic markets, including the treatment of sarcopenia, cachexia, anorexia, obesity and muscular-related conditions; and, conducting research and development focused on the discovery, development and commercialization of other products and technologies aimed at maintaining or improving the health and performance of muscle tissue. Since its inception in April 2007, the Company has recognized revenues of $7,672. The Company’s activities are subject to significant risks and uncertainties.
	Our commercial focus is to leverage our clinical data to develop proprietary products including direct-to-consumer branded products using multiple product delivery formats to target the large, but currently underserved, markets focused on muscle health. Our first commercial product, MYO-T12, is currently sold in the sports nutrition market through an agreement with Maximum Human Performance (“MHP”), a company engaged in the development, marketing and distribution of nutritional and other supplemental products for consumer use. MHP distributes MYO-T12 principally in the U.S. under the brand name MYO-X®, which is currently available on retailer websites and in specialty retailers. In February 2014, we expanded our commercial operations into the age management market through an agreement with Cenegenics Product and Lab Services, LLC (“Cenegenics”). Under the distribution agreement, Cenegenics agreed to exclusively distribute and promote a proprietary formulation of Fortetropin through its age management centers in the U.S. and its community of physicians focused on treating a growing population of patients focused on proactively addressing age-related health and wellness concerns.
	While we may continue to sell our products through distributors, we expect to continue developing our own core branded products, which we anticipate launching at the end of the first quarter of 2015, and to pursue additional markets such as medical foods and international opportunities. Our direct-to-consumer portfolio of branded products will feature a line of muscle health bars, meal replacement shakes and daily supplement powders each powered by a full 6.6 gram single serving of Fortetropin. Initially, our branded products will be sold through online ecommerce and marketed through targeted digital direct advertising, which we anticipate will support future expansion into retail channels. The growing awareness of the potential therapeutic uses of myostatin inhibition supports continued development of our own core branded products. We remain committed to continuing our focus on various clinical trials in support of our marketing claims as well as to enhance our intellectual property, to develop product improvements and new products and to reduce the cost of our products by finding more efficient manufacturing processes and contract manufacturers.
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the consolidated financial statements included in this report.
	Liquidity
	As of December 31, 2014, the Company had cash of $1,567 to meet current obligations and working capital of $4,534 (current assets of $5,108, less current liabilities of $574). We have incurred net losses since our inception. For the years ended December 31, 2014 and 2013 our net loss was $4,459 and $4,263, respectively. In addition, net cash used in operating activities for the years ended December 31, 2014 and 2013 was $5,089 and $3,154, respectively. At December 31, 2014 and 2013, we had an accumulated deficit of $18,367 and $13,908, respectively. Since the Company’s inception, net cash provided by financing activities, which has been our primary source of cash flows, was $15,345. As of the filing date of this Form 10-K, management believes that there may not be sufficient capital resources from operations and existing financing arrangements in order to meet operating expenses and working capital requirements for the next twelve months. We expect that we will need to seek additional funding through public or private financing or through collaborative arrangements with strategic partners in the second quarter of 2015 as we do not expect to have sufficient cash to operate past such date. These facts raise substantial doubt about the Company’s ability to continue as a going concern. Accordingly, we are evaluating various alternatives, including reducing operating expenses and personnel costs, securing additional financing for future business activities and other strategic alternatives.
	There can be no assurance that the Company will be able to generate the level of operating revenues in its business plan, or if additional sources of financing will be available on acceptable terms, if at all. If no additional sources of financing are available, our future operating prospects may be adversely effected. No adjustments have been made to these financial statements to reflect this uncertainty.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of MYOS Corporation and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions between and among its consolidated subsidiary have been eliminated.
	Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, measurement of allowances for doubtful accounts and inventory reserves, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities.
	The Company currently cannot predict what future sales, if any, will come from the Company's distributors. In addition, the Company plans to launch its direct-to-consumer branded products at the end of the first quarter of 2015. Management's estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts.
	Cash & Cash Equivalents
	As of December 31, 2014 and 2013, the Company had cash of $1,567 and $451, respectively. The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At December 31, 2014 and 2013, the Company had no cash equivalents.
	The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. The balance at times may exceed federally insured limits. At December 31, 2014 and 2013, the Company's uninsured cash balances totaled $1,292 and $197, respectively.
	Concentrations of Risk, Significant Customers and Significant Supplier
	The Company currently sells its products primarily through two distributors, MHP and Cenegenics. Credit risk is concentrated among these customers. The Company monitors economic conditions and performs ongoing credit evaluation of its customers. Management regularly reviews accounts receivable, and if necessary, establishes an allowance for doubtful accounts that reflects management’s best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Bad debt expense recognized as a result of an allowance for doubtful accounts is classified under selling, general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. If we are unable to collect the outstanding accounts receivable from our distributors, or if our distributors are unable or unwilling to purchase our products and we are unable to secure alternative customers, our operating results and financial condition will be adversely affected.
	Bad debt expense was $390 and $0 for the years ended December 31, 2014 and 2013, respectively. Bad debt expense for the year ended December 31, 2014 related to recording an allowance for doubtful accounts against existing accounts receivable balance of Cenegenics based on management’s best estimate of amounts that may not be collectible.
	At December 31, 2014 and 2013, the Company had the following concentrations of net accounts receivable with customers:
			December 31,			December 31,
			2014			2013
	MHP		$	-		$	645
	Cenegenics			1,372			-
	Subtotal			1,372			645
	Allowance for doubtful accounts			(390	)		-
	Accounts receivable, net		$	982		$	645
	For the years ended December 31, 2014 and 2013, the Company had the following concentrations of revenues with customers:
			Years Ended December 31,
			2014			2013
	MHP			36	%		100	%
	Cenegenics			63	%		0	%
	Other			1	%		0	%
	Total			100	%		100	%
	The Company currently relies on one third-party manufacturer to produce Fortetropin (see Note 12 – Commitments and Contingencies - Supply Agreement). This manufacturer purchases all the needed raw materials from suppliers and coordinates any additional production steps with third-parties. We have multiple vendors for blending, packaging and labeling. The Company is pursuing other supply alternatives.
	Inventories, net
	Inventories are valued at the lower of cost or market, with cost determined on a first in, first-out basis. The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors.
	Fixed Assets
	Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the Consolidated Statements of Operations and Comprehensive Loss.
	Depreciation is provided using the straight-line method for all fixed assets.
	We review our fixed assets for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. If the assets are determined to be unrecoverable, an impairment loss is calculated by determining the difference between the carrying values and the estimated fair value. Included in the year ended December 31, 2014, was an impairment charge of $5 to reduce the unrecoverable net carrying value of a capitalized fixed asset to zero. We did not consider any of our property and equipment to be impaired during the year ended December 31, 2013.
	Intangible Assets
	The Company’s intangible assets primarily relate to intellectual property pertaining to Fortetropin, including the MYO-T12 formula, trademarks, trade secrets, patent application and domain names acquired from Peak Wellness, Inc. in February 2011. The intellectual property asset was initially recorded as an indefinite-lived intangible asset and tested annually during the fourth quarter for impairment or more frequently if events or circumstances changed that could potentially reduce the fair value of the asset below its carrying value. In 2011, based on (i) assessment of current and expected future economic conditions, (ii) trends, strategies and projected revenues and (iii) assumptions similar to those that market participants would make in valuing the Company's intangible assets, management determined that the carrying values of the intellectual property asset exceeded its fair value. Accordingly, the Company recorded noncash impairment charges totaling $2,662 and reduced the intellectual property asset to its fair value of $2,000. Management performed annual impairment tests in 2012 and 2013 and determined no further impairment existed. During the second quarter of 2014, management made an assessment and based on expansion into new markets and introduction of new formulas determined that the intellectual property had a finite useful life of ten (10) years and began amortizing the carrying value of the intellectual property asset over its estimated useful life. Management made a separate determination that no further impairment existed at the time. Based on two consecutive quarters of minimal revenues combined with our history of operating losses, we tested the intellectual property asset for impairment again in the fourth quarter of 2014 and determined that the asset value was recoverable and therefore, no impairment loss was recognized.
	Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows, selection of the appropriate discount rate to measure the risk inherent in future cash flow streams, assessment of an asset’s life cycle, competitive trends impacting the asset as well as other factors. Changes in these underlying assumptions could significantly impact the asset’s estimated fair value.
	In July 2014, the Company acquired the United States patent application for the manufacture of Fortetropin from Deutsches Institut fur Lebensmitteltechnik e.V. - the German Institute for Food Technologies (“DIL”). The cost of the patent application, which was capitalized as an intangible asset, was determined to be $101, based on the present value of the minimum guaranteed royalty payable to DIL using a discount rate of 10%. The intangible asset will be amortized over an estimated useful life of ten (10) years. The remaining contingent royalty payments will be recorded as the contingency is resolved and the royalty becomes payable under the arrangement. For additional information on the amended supply agreement with DIL refer to “Note 12 – Commitments and Contingencies - Supply Agreement.”
	Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor’s patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years.
	Intangible assets at December 31, 2014 and December 31, 2013 consisted of the following:
	(In thousand $)		December 31,			December 31,
			2014			2013
	Intangibles with finite lives:
	Intellectual property		$	2,101		$	-
	Less:  accumulated amortization			(155	)		-
	Total intangibles with finite lives:			1,946			-
	Intangibles with indefinite lives:
	Intellectual property			-			2,000
	Patent costs			44			38
	Total intangibles with indefinite lives:			44			2,038
	Total intangible assets, net		$	1,990		$	2,038
	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense for intangible assets is estimated to be $210 in each of the next five years.
	Revenue Recognition
	The Company records revenue when persuasive evidence of an arrangement exists, product has been shipped or delivered, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Depending on individual customer agreements, sales are recognized either upon shipment of product to customers or upon delivery. The Company’s gross product sales may be subject to sales allowances and deductions in arriving at reported net product sales. Reductions from gross sales for customer discounts and rebates have been minimal, and sales allowances for product returns have not been provided, since under our existing arrangements, customers are not permitted to return product except for non-conforming product.
	Research and Development
	Research and development expenses consist primarily of salaries, benefits, and other related costs, including stock-based compensation, for personnel serving in our research and development functions, and other internal operating expenses, the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed.
	Advertising
	The Company charges the costs of advertising to selling, general and administrative expense as incurred. Advertising and promotional costs, which consist primarily of co-operative advertising fees payable to MHP, were $732 and $1,659 for the years ended December 31, 2014 and 2013, respectively. Pursuant to our distribution agreement with MHP, the Company has a co-operative advertising arrangement whereby the Company pays MHP a fee for each unit sold.
	Shipping and Handling Costs
	The Company records costs of shipping product to our distributors in cost of sales. These expenses were $10 and $0 for the years ended December 31, 2014 and 2013, respectively.
	Foreign Currency
	Our revenues are generated in U.S. dollars, while a significant portion of our expenses may be incurred in foreign currencies, principally the payments to our primary manufacturer that are paid in euros. Foreign currency gains resulting from transactions denominated in a currency other than the functional currency were $42 and $0 for the years ended December 31, 2014 and 2013, respectively, and are included in selling, general and administrative expense, net in the accompanying consolidated statements of operations.
	Stock-based Compensation
	Generally, stock-based payments are measured at their estimated fair value on the date of grant. Stock-based awards to non-employees are re-measured at fair value each financial reporting date until performance is complete. Stock-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period.
The Company uses the Black-Scholes option-pricing model to estimate the fair value of options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
Stock-based compensation expense for awards to employees and non-employees was $1,691 and $1,335 for the years ended December 31, 2014 and 2013, respectively.
Comprehensive Loss
Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by, or distributions to, the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that are included in comprehensive income (loss), but excluded from net loss as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company had no other comprehensive income (loss) items for the years ended December 31, 2014 and 2013. Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.
Segment Information
Accounting Standards Codification (“ASC”) 280, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information about operating segments and requires selected information for those segments to be presented in the financial statements. It also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. Management has determined that the Company operates in one segment.
Fair Value Measurement
Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level.
The following are the hierarchy levels of inputs to measure fair value:
	Level 1:	Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.
	Level 2:	Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active.
	Level 3:	Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity.
A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At December 31, 2014 and 2013, the Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. Due to their short-term nature, the carrying amounts of the Company’s financial instruments approximated their fair values.
Basic and Diluted Loss Per Share
Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the “treasury stock” method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the years ended December 31, 2014 and 2013, the Company incurred a net loss. Accordingly, the Company’s common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at December 31, 2014 and 2013 but excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,541,330 and 232,320, respectively.
Income Taxes
Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized.
The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement. This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions. The Company has no uncertain income tax positions.
Interest costs and penalties related to income taxes are classified as interest expense and operating expenses, respectively, in the Company's financial statements. For the years ended December 31, 2014 and 2013, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.
Reclassifications
The Company has revised the presentation of “Selling, General and Administrative Expenses” within the Consolidated Statements of Operations for the year ended December 31, 2013 to conform to the current year presentation. Research and development expenses of $754 for the year ended December 31, 2013, were previously not presented separately. This reclassification was for presentation purposes and had no effect on the financial position, results of operations, or cash flows for the period presented.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2014
Recent Accounting Pronouncements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 3 – RECENT ACCOUNTING PRONOUNCEMENTS
	In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2014-15 – Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 defines management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and provides related footnote disclosure requirements. Under U.S. GAAP, financial statements are prepared under the presumption that the reporting organization will continue to operate as a going concern, except in limited circumstances. Financial reporting under this presumption is commonly referred to as the going concern basis of accounting. The going concern basis of accounting establishes the fundamental basis for measuring and classifying assets and liabilities. The Update provides guidance on when there is substantial doubt about an organization’s ability to continue as a going concern and how the underlying conditions and events should be disclosed in the footnotes. It is intended to reduce diversity that existed in footnote disclosures because of the lack of guidance about when substantial doubt existed. The amendments in this Update is effective for us beginning in the first quarter of 2017. Early application is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.
	In June 2014, the FASB issued Accounting Standards Update 2014-10 – Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation ("ASU 2014-10"). The amendments in this update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification. In addition, the amendments eliminate the requirements for development stage entities to (i) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. For other entities, the amendments are effective for annual reporting periods beginning after December 15, 2014, and interim reporting periods beginning after December 15, 2015. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer be required to present or disclose any information required by Topic 915.
	The Company has early adopted ASU 2014-10 commencing with its financial statements for the quarter ended June 30, 2014.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP and requires revenue to be recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance will become effective for us beginning in the first quarter of 2017 using one of two prescribed transition methods. Early adoption is not permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.

Inventories_Net

Inventories, Net	12 Months Ended
	Dec. 31, 2014
Inventories, Net [Abstract]
INVENTORIES, NET	NOTE 4 – INVENTORIES, NET
	Inventories, net at December 31, 2014 and 2013 consisted of the following:
	(In thousand $)	December 31,			December 31,
		2014			2013
	Raw materials	$	1,638		$	137
	Work in process		2			-
	Finished goods		443			6
			2,083			143
	Less: inventory reserves		(269	)		-
	Inventories, net	$	1,814		$	143
	Inventories at December 31, 2014 increased compared to December 31, 2013 primarily due to a production campaign to build inventories in anticipation of launching our own core branded products in 2015. During 2014, the Company recorded inventory reserves of $269 related to slow-moving and off-grade inventories and packaging materials manufactured for MHP and Cenegenics. There was no inventory reserves recorded for the year ended December 31, 2013.

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2014
Fixed Assets [Abstract]
FIXED ASSETS	NOTE 5 – FIXED ASSETS
	Fixed assets at December 31, 2014 and 2013 consisted of the following:
	(In thousand $)	December 31,			December 31,
		2014			2013
	Furniture, fixtures and equipment	$	134		$	127
	Computers and software		21			17
	Leasehold improvements		239			234
	Other		7			5
	Total fixed assets		401			383
	Less: accumulated depreciation		(88	)		(39	)
	Net book value of fixed assets	$	313		$	344
	Depreciation expense was $49 and $37 for the years ended December 31, 2014 and 2013, respectively. Repairs and maintenance costs are expensed as incurred.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt [Abstract]
DEBT	NOTE 6 – DEBT
	Revolving Note
	On August 29, 2014, the Company entered into a Loan Revision Agreement, which extended the termination date of the October 2013 revolving credit agreement (as amended, the “Revolving Note”) with City National Bank to August 31, 2015. All other terms evidenced by the Revolving Note remained the same. The Revolving Note provides an aggregate principal amount of $500 in revolving loans collateralized by all inventory, chattel paper, accounts, equipment, general intangibles, securities and instruments. The revolving loans may be borrowed, repaid and re-borrowed, provided at the time of any borrowing no event of default exists. Under the Revolving Note, all principal amounts outstanding with interest thereon is due and payable on August 31, 2015. Committed borrowings under the Revolving Note bear interest from the date of its disbursement at a per annum interest rate equal to prime rate plus 1.25%. The Revolving Note contains customary events of default, including failure to make payment and bankruptcy. At December 31, 2014 and 2013, there were no outstanding borrowings under the Revolving Note. As of the date of this filing, up to $500 of borrowings under the Revolving Note are still available to the Company.

Prepaid_Expenses_Other_Current

Prepaid Expenses, Other Current Assets and Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Prepaid Expenses, Other Current Assets and Accrued Expenses [Abstract]
PREPAID EXPENSES, OTHER CURRENT ASSETS AND ACCRUED EXPENSES	NOTE 7 - PREPAID EXPENSES, OTHER CURRENT ASSETS AND ACCRUED EXPENSES
	Prepaid Expenses and Other Current Assets
	Prepaid expenses and other current assets consist of various payments that the Company has made in advance for goods or services to be received in the future. Prepaid expenses and other current assets at December 31, 2014 and 2013 consisted of the following:
	(In thousand $)	December 31,		December 31,
		2014		2013
	Prepaid insurance	$	46	$	63
	Prepaid research and development		15		-
	Prepaid stock compensation		-		70
	Prepaid consulting		8		20
	Prepaid inventory purchases		664		-
	Other		12		62
	Total prepaid expenses and other current assets	$	745	$	215
	Accrued Expenses
	Accrued expenses consist of estimated future liability payments that relate to the current and prior accounting periods. Management reviews these estimates regularly to determine their reasonableness. Accrued expenses at December 31, 2014 and 2013 consisted of the following:
	(In thousand $)	December 31,		December 31,
		2014		2013
	Advertising and promotional expense payable	$	171	$	171
	Audit fees payable		25		35
	Rent payable		30		30
	Research & development		49		-
	Accrued salaries & bonuses		92		-
	Consulting fees payable		96		65
	Other accrued expenses		32		11
	Total accrued expenses	$	495	$	312

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 8 - STOCKHOLDERS’ EQUITY
	Reverse Stock Split
	On February 5, 2014, the Company filed a Certificate of Change with the Secretary of State of the State of Nevada to effect a reverse stock split of its outstanding and authorized shares of common stock and preferred stock at a ratio of 1 for 50. As a result of the reverse stock split, the number of the Company’s authorized shares of common stock decreased from 300,000,000 to 6,000,000 shares and the number of its authorized shares of preferred stock decreased from 25,000,000 to 500,000 shares. All amounts presented in these financial statements have been adjusted for the reverse stock split.
	Increase in Number of Authorized Shares
	On December 22, 2014, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada to increase the number of authorized shares of common stock. As a result of the amendment, the number of the Company’s authorized shares of common stock increased from 6,000,000 to 8,000,000.
	Offerings of Common Stock
	The Company has periodically issued common stock in connection with certain private and public offerings. The Company has received aggregate gross proceeds of approximately $15.9 million from these offerings as follows:
	(In thousand $)
					Gross
	Date		Shares		Proceeds
	25-Feb-11			95,334	$	1,430
	31-May-11			28,200		423
	27-Jun-11			37,500		563
	12-Jul-11			1,667		25
	2-Dec-11			4,000		40
	10-Feb-12			65,000		325
	14-Feb-12			80,000		400
	7-Mar-12			20,000		100
	15-Mar-12			35,000		175
	22-Mar-12			5,000		25
	9-Apr-12			20,000		100
	24-Apr-12	*		4,000		-
	28-Jun-12			48,000		600
	6-Jul-12			411,600		5,145
	27-Jan-14			631,346		4,735
	19-Nov-14			193,865		1,816
				1,680,512	$	15,902
	* Shares issued under price protection agreement
	Private Placement Proceeds
	In January 2014, the Company issued an aggregate of 631,346 shares of common stock and granted two series of warrants (Series A and Series B) to purchase 315,676 and 157,846 shares of common stock, respectively, to certain accredited investors in a private placement and received aggregate gross proceeds of $4,735, or $4,663 net of offering costs. The Series A warrants have a three year term and are exercisable at $15.00 per share. The Series B warrants have a five year term and are exercisable at $45.00 per share. For additional information on the Series A warrants and Series B warrants refer to “Note 9 – Warrants.” The securities were subject to registration rights and have been registered. Brean Capital, LLC (“Brean”) served as placement agent in the private placement and was issued 47,351 shares of common stock with a fair value of $355 based on the market price of our common stock on the date of grant as its fee, or 7.5% of the shares of common stock issued in the private placement.
	Public Offering
	In November 2014, the Company issued an aggregate of 193,865 units consisting of: (i) one share of our common stock; (ii) one Series C common stock warrant to purchase 0.75 shares of our common stock; (iii) one Series D common stock warrant to purchase one share of our common stock; and, (iv) one Series E common stock warrant to purchase 0.75 shares of our common stock, at a public offering price of $9.37 per unit to institutional and accredited investors in a registered-direct public offering. In addition, the Company is required to issue to the purchasers up to 193,865 additional shares of common stock in the event that the closing price of our common stock is below $14.06 (subject to adjustment) on the twelve month anniversary of the date of issuance, provided that the purchasers continue to hold at least a portion of the shares of common stock issued in the offering on such date (the “Make-Whole Shares”). The Company assessed the warrants and Make-Whole Share provisions and concluded that the warrants and Make-Whole Shares qualified for equity treatment. The Company received aggregate gross proceeds of $1,816, or $1,571 net of offering costs. Each Series C warrant has an exercise price of $12.00 per share, is exercisable subsequent to the six-month anniversary of the date of issuance and separately transferable from the shares and expires on the sixty-sixth month anniversary of the date of issuance. Each Series D warrant has an exercise price of $9.37 per share, is immediately exercisable and separately transferable from the shares, may be redeemed by us in the event that the closing price of our stock is $12.00 or above for 20 consecutive trading days (subject to certain minimum trading volume requirements), and expires on the six month anniversary of the date of issuance. Each Series E warrant is exercisable only if the Series D warrants are exercised, has an exercise price of $15.00 per share, is exercisable subsequent to the six month anniversary of the date of issuance and separately transferable from the shares and expire on the 90-month anniversary of the date of issuance. Chardan Capital Markets, LLC served as placement agent in the offering. The Company agreed to pay a placement fee equal to 7.0% of the aggregate gross proceeds of the offering and from the cash exercise of the Series D common stock warrants in the event such warrants are exercised and 3.5% of the aggregate gross proceeds from investors who were previously introduced to the Company by Brean. Pursuant to the Company’s prior engagement letter with Brean, Brean received a fee equal to 7.0% of the aggregate purchase price paid by Purchasers in the offering that Brean previously introduced to the Company through the January 2014 private placement. For additional information on the Series C, Series D and Series E warrants refer to “Note 9 – Warrants.”

Warrants

Warrants	12 Months Ended
	Dec. 31, 2014
Warrants [Abstract]
WARRANTS	NOTE 9 – WARRANTS
	On January 27, 2014, in connection with a private placement (refer to “Note 8 - Stockholders’ Equity – Private Placement Proceeds”), the Company granted warrants to purchase an aggregate of 473,522 shares of common stock as follows: (i) Series A warrants to purchase 315,676 shares of common stock at an exercise price of $15.00 per share (the “Series A Warrant”) and (ii) Series B warrants to purchase 157,846 shares of common stock at an exercise price of $45.00 per share (the “Series B Warrant”). The warrants were determined to have an estimated aggregate fair value of $2,486. The Series A Warrants entitle the holders to purchase shares of common stock for a period of three years from the grant date and the Series B Warrants entitle the holders to purchase common stock for a period of five years from the grant date. The warrants can also be exercised on a cashless basis.
	On November 19, 2014 in connection with a registered-direct public offering (refer to “Note 8 - Stockholders’ Equity – Public Offering”), the Company granted warrants to purchase an aggregate of 484,663 shares of common stock as follows: (i) Series C warrants to purchase 145,399 shares of common stock at an exercise price of $12.00 per share (the “Series C Warrant”), (ii) Series D warrants to purchase 193,865 shares of common stock at an exercise price of $9.37 per share (the “Series D Warrant”), (iii) Series E warrants to purchase 145,399 shares of common stock at an exercise price of $15.00 per share (the “Series E Warrant. The Series C, Series D and Series E warrants were determined to have an estimated aggregate fair value of $969, $470, and $1,048, respectively. The Series C Warrants entitle the holders to purchase shares of common stock for a period of 66-months from the grant date, The Series D Warrants entitle the holders to purchase shares of common stock for a period of 6-months from the grant date and the Series E Warrants entitle the holders to purchase shares of common stock for a period of 90-months from the grant date.In addition, the Company granted Make-Whole Shares, which provides for the issuance of up to 193,865 additional shares of common stock in the event that the closing price of our common stock is below $14.06 (subject to adjustment) on the twelve month anniversary of the date of issuance. The Make-Whole Shares, which were determined to have an estimated fair value of $1,049 as of the issuance date, qualified for equity accounting treatment since the economic characteristics of the Make-Whole Shares were determined to be clearly and closely related to the economic characteristics of our common stock under ASC 815, "Derivatives and Hedging." Accordingly the Make-Whole Shares were not bifurcated and accounted separate from the issued shares.
	The following table summarizes information about warrants granted during 2014 and outstanding and exercisable at December 31, 2014.
				Number of				Shares Underlying		Shares Underlying		Shares Underlying
				Shares				Warrants		Warrants		Warrants
				Underlying				Exchanged,		Outstanding		Exercisable at					Expiration
				Warrants				Exercised		at December,		December 31,		Exercise			Term in
	Description	Grant Date		Granted				or Expired		2014		2014		Price			Years
	Series A	27-Jan-14			315,676				-		315,676		315,676	$	15			2.08
	Series B	27-Jan-14			157,846				-		157,846		157,846	$	45			4.07
	Series C	19-Nov-14			145,399				-		145,399		-	$	12			5.38
	Series D	19-Nov-14			193,865				-		193,865		193,865	$	9.37			0.38
	Series E	19-Nov-14			145,399				-		145,399		-	$	15			7.38
					958,185				-		958,185		667,387
	The following table summarizes the activities in warrants for the years ended December 31, 2014 and 2013:
						Weighted
		Shares				Average
		Underlying				Exercise
		Warrants				Price
	Balance at December 31, 2012		3,000			$	50
	Warrants granted		-				-
	Warrants exercised		-				-
	Warrants cancelled/exchanged/expired		(3,000	)			50
	Balance at December 31, 2013		-			$	-
	Warrants granted		958,185				18.35
	Warrants exercised		-				-
	Warrants cancelled/exchanged/expired		-				-
	Balance at December 31, 2014		958,185			$	18.35
	The following table summarizes the assumptions used to value the warrants at the issuance date using the Black-Scholes option pricing model:
				Number of Shares				Stock
				Underlying				Price on
				Warrants				Measurement		Exercise		Expected		Expected			Dividend			Risk Free
	Description	Grant Date		Granted				Date		Price		Term		Volatility			Yield			Rate
	Series A	1/27/2014			315,676			$	7	$	15		3		150	%		0	%		0.76	%
	Series B	1/27/2014			157,846			$	7	$	45		5		150	%		0	%		1.61	%
	Series C	11/19/2014			145,399			$	9.37	$	12		5.5		94.6	%		0	%		1.64	%
	Series D	11/19/2014			193,865			$	9.37	$	9.37		0.5		93.44	%		0	%		0.07	%
	Series E	11/19/2014			145,399			$	9.37	$	15		7.5		94.6	%		0	%		1.64	%
					958,185
	A Monte-Carlo Simulation Model was used to estimate the fair value of the Make-Whole Shares. The model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time equal to the remaining contractual term of the instrument granted. The following table summarizes the principal assumptions used in applying the model to estimate the fair value of the Make-Whole Shares at the issuance date:
	Volatility		95	%
	Risk-Free Interest Rate		1.47	%
	Expected Term in Years		1.00 years
	Dividend Rate		0	%
	Fair Value of Common Stock Share	$	9.37

Stock_Compensation

Stock Compensation	12 Months Ended
	Dec. 31, 2014
Stock Compensation [Abstract]
STOCK COMPENSATION	NOTE 10 - STOCK COMPENSATION
	Equity Incentive Plan
	In November 2012, the Company’s stockholders approved the 2012 Equity Incentive Plan, (as amended, the “Plan”). On December 18, 2014, the Company’s stockholders approved a proposal to increase the number of shares of our common stock available for future issuance under the Plan to 550,000 shares. The Plan provides for grants of stock options, stock appreciation rights, restricted stock, other stock-based awards and other cash-based awards. The Company believes that such awards better align the interests of its employees and directors with those of its shareholders. As of December 31, 2014, the maximum number of shares of common stock reserved for future grant of awards under the Plan was 212,920. The Company granted an aggregate of 30,000 options to purchase restricted common stock to certain directors prior to the adoption of the Plan. As of December 31, 2014, all options granted outside of the Plan have vested. As of December 31, 2014, options to purchase 337,080 shares of the Company's stock have been granted under the Plan.
	The following table summarizes stock option activity for the years ended December 31, 2014 and 2013:
											Weighted
							Weighted				Average
			Shares				Average				Remaining
			Under				Exercise				Contractual
			Options				Price				Term (Years)
	Balance at December 31, 2012			30,160			$	26.58
	Options granted			202,200			$	14.58
	Options exercised			-
	Options forfeited			(40	)		$	10
	Balance at December 31, 2013			232,320			$	16.14				8.98
	Options granted			146,560				11.83
	Options exercised			-				-
	Options cancelled/forfeited			(11,800	)			8.09
	Balance at December 31, 2014			367,080			$	14.68				8.5
	At December 31, 2014 and 2013, the aggregate intrinsic value of exercisable options was $0 and $4, respectively. The aggregate intrinsic value is calculated by multiplying the number of outstanding and exercisable options by the excess of the market price for our common stock over the exercise price for each option. At December 31, 2014 and 2013, the market price for our common stock was $6.90 and $7.50, respectively.
	The weighted average grant date fair value of stock options granted during 2014 and 2013 was $10.62 and $9.47, respectively. The following table summarizes the assumptions used to value stock options granted during 2014 and 2013 using a Black-Scholes model:
			2014				2013
	Risk-free interest rate			1.63%-2.84%				1.80%-2.89%
	Expected volatility			145%-151%				152%-166%
	Weighted average expected volatility			148	%			163	%
	Expected term (years)			5.63-10.0				10
	Expected dividend yield			0	%			0	%
	The risk-free rate is based on the U.S. Treasury rate for a note with a similar term in effect at the time of the grant. The expected volatility is based on the volatility of the Company’s historical stock prices.
	The following table summarizes information about options outstanding and exercisable at December 31, 2014 that were granted under the Plan:
	Options Outstanding												Options Exercisable
									Weighted Average								Weighted Average
	Range of				Options				Remaining				Range of		Options		Remaining
	Exercise Price				Outstanding				Contractual Life				Exercise Price		Exercisable		Contractual Life
	$	7				5,000				7.39			$	7		5,000		7.39
	$	8.6				30,500				9.2			$	8.6		7,625		9.2
	$	10				9,320				8.06			$	10		7,653		8.06
	$	11				3,000				8.03			$	11		1,500		8.03
	$	12.1				30,500				9.36			$	12.1		7,625		9.36
	$	12.5				106,200				8.46			$	12.5		58,509		8.43
	$	12.55				20,000				9.39			$	12.55		-		-
	$	13				14,600				9.53			$	13		3,650		9.53
	$	13.45				2,000				9.48			$	13.45		-		-
	$	13.5				14,960				9.49			$	13.5		-		-
	$	13.75				6,000				9.68			$	13.75		-		-
	$	17.5				100,000				8.11			$	17.5		50,000		8.11
	$	22.5				5,000				6.62			$	22.5		5,000		6.62
	$	32				15,000				6.53			$	32		15,000		6.53
	$	34.5				5,000				6.56			$	34.5		5,000		6.56
						367,080										166,562
	As of December 31, 2014, 166,562 options have vested and 200,518 options remain unvested. The vesting terms range from zero to 3.5 years and the vested options have a weighted average remaining term of 8.1 years and a weighted average exercise price of $14.75 per share.
	Stock-based compensation was $1,691 and $1,335 for the years ended December 31, 2014 and 2013, respectively. The following table summarizes the components of stock-based compensation in the statements of operations for the years ended December 31, 2014 and 2013:
			2014				2013
	Cost of sales		$	-			$	-
	Research and development			123				8
	Selling, general and administrative			1,568				1,327
	Total stock-based compensation		$	1,691			$	1,335
	The aggregate unrecognized compensation expense of options at December 31, 2014 was $1,092, which will be recognized through June 2018.
	Restricted Stock Issuances
	During the year ended December 31, 2014, the Company issued an aggregate of 13,200 shares of restricted common stock. All such shares were valued at trading prices on the date of issuance between $7.50 and $14.39 per share and are subject to certain vesting requirements. The compensation cost for unvested restricted stock, which is included in the stock-based compensation amounts indicated above, was $197 and $289 for the years ended December 31, 2014 and 2013, respectively.
	The following table summarizes the activities in restricted stock awards granted (under the Plan) during the year ended December 31, 2014:
							Weighted
							Average
							Grant Date
			Shares				Share Price
	Restricted stock awards unvested at December 31, 2012			35,700			$	16.21
Granted			26,780				7.39
Vested			(30,030	)			9.7
Forfeited			-				-
Restricted stock awards unvested at December 31, 2013			32,450			$	14.96
Granted			13,200				7.79
Vested			(13,450	)			13.86
Forfeited			(10,000	)			7
Restricted stock awards unvested at December 31, 2014			22,200			$	14.95
At December 31, 2014, the weighted-average remaining vesting period of unvested restricted stock awards was 1.92 years. The aggregate unrecognized compensation expense of unvested restricted stock at December 31, 2014 was $248, which will be recognized through February 2018.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
INCOME TAXES	NOTE 11 - INCOME TAXES
	Income tax expense for the years ended December 31, 2014 and 2013 is shown as follows:
	(In thousand $)
	Years ended December 31,	2014			2013
	Current provision	$	(748	)	$	-
	Deferred provision		-			-
	Total tax provision (benefit)	$	(748	)	$	-
	Included in the year ended December 31, 2014 is an income tax benefit resulting from the reversal of a valuation allowance previously recorded against the Company’s New Jersey State net operating losses (“NOL”) that resulted from the Company’s sale of $8,890 of its New Jersey State NOLs and $15 of its unused research and development tax credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) for cash of $750, net of commissions. The Program allows qualified technology and biotechnology businesses in New Jersey to sell unused amounts of NOLs and defined research and development tax credits for cash. The remaining net deferred tax asset as of December 31, 2014 remains fully offset by a valuation allowance due to the Company’s history of losses.
	The significant components of the Company's deferred tax assets and liabilities at December 31, 2014 and 2013 are as follows:
	(In thousand $)	2014			2013
	Federal net operating losses	$	3,997		$	3,042
	State net operating losses		160			531
	Stock options		1,104			-
	Federal tax credit		110			-
	Amortization		508			560
	Depreciation		(12	)		(16	)
	Contributions		13			4
	Total gross deferred tax assets/(liabilities)	$	5,880		$	4,121
	Less valuation allowance		(5,880	)		(4,121	)
	Net deferred tax assets/(liabilities)	$	-		$	-
	The income tax benefit for the year ended December 31, 2014 differed from the amounts computed by applying the U.S. federal income tax rate of 34% to loss before tax benefit as a result of nondeductible expenses, tax credits generated, utilization of net operating loss carryforwards, and increases in the Company’s valuation allowance.
	(In thousand $)	2014			2013
		($)			($)
	Federal statutory rate	$	(1,770	)	$	(1,450	)
	Sale of NJ NOL/credits		(495	)		-
	Permanent differences		136			50
	Research and development		(110	)		-
	State taxes		1			-
	Stock compensation		(584	)		-
	Valuation allowance		2,074			1,400
	Effective tax rate	$	(748	)	$	-
	A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of the available evidence, both positive and negative, the Company determined that valuation allowances of $5.9 million and $4.1 million at December 31, 2014 and 2013, respectively, were necessary to reduce the deferred tax assets to the amount that will more likely than not be realized.
	At December 31, 2014 and 2013, the Company had approximately $11.8 million and $9.1 million of gross federal net operating loss carry-forwards, respectively. At December 31, 2014 and 2013, the Company had approximately $2.7 million and $8.9 million of gross state net operating loss carry-forwards, respectively. If not utilized, the federal and state net operating loss carry-forwards will begin to expire in 2027. The utilization of such net operating loss carry-forwards and realization of tax benefits in future years depends predominantly upon having taxable income. The Company also has approximately $110 of federal research and development credits which will begin to expire in 2033 if not utilized.
	The Company may be subject to the net operating loss provisions of Section 382 of the Internal Revenue Code. The Company has not calculated if an ownership change has occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company’s capital during a specified period, and the federal published interest rate.
	Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2014 there were no uncertain positions. The federal and state income tax returns of the Company for 2011, 2012 and 2013 are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed. In years where a NOL is generated, the statute remains open with respect to the NOL until three years after the NOL is utilized. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. There was no income tax related interest and penalties included in the income tax provision for 2014 and 2013.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES
	Operating Lease
	On June 6, 2014, the Company entered into the First Amendment to Commercial Lease (the “Amendment”), which amends the operating lease of the Company’s corporate offices entered into on August 1, 2012. The Company entered into the Amendment to (a) lease additional space located adjacent to the Company’s current corporate offices and (b) extend the term of the lease. Under the Amendment, the additional leased space is approximately 9,079 square feet, bringing the total leased premises to approximately 14,304 square feet. The term of the lease for the additional space is five years commencing on January 1, 2015 and expiring on December 31, 2019. The initial base rent for the additional space will be approximately $9 per month, subject to the increases set forth in the Amendment. The Company will receive rent abatement for the first three months of occupancy during each of 2015 and 2016 for the additional space. The Amendment also extends the lease of the original space from July 31, 2017 through December 31, 2019. The base rent for the original space as of August 1, 2014 was approximately $5 per month, subject to annual increases.
	The future minimum lease payments under the non-cancellable operating lease in excess of one year at December 31, 2014 is as follows:
	(In thousand $)
	Years Ended December 31,	Amount
	2015	$	150
	2016		152
	2017		181
	2018		187
	2019		191
	Total	$	861
	Rent expense including common area maintenance charges and taxes for the years ended December 31, 2014 and 2013 was $75 and $70, respectively.
	Defined Contribution Plan
	The Company established a 401(K) Plan (the “401(K) Plan”) for eligible employees of the Company effective April 1, 2014. Generally, all employees of the Company who are at least twenty-one years of age and who have completed three months of service are eligible to participate in the 401(K) Plan. The 401(K) Plan is a defined contribution plan that provides that participants may make salary deferral contributions, of up to the statutory maximum allowed by law (subject to catch-up contributions) in the form of voluntary payroll deductions. The Company’s matching contribution is equal to 100 percent on the first four percent of a participant’s compensation which is deferred as an elective deferral. The Company’s aggregate matching contribution for the year ended December 31, 2014 was $26.
	Sponsorship Agreement
	On June 27, 2011, the Company entered into a one year agreement with a celebrity spokesperson pursuant to which the spokesperson agreed to perform certain services for the Company and granted the Company the worldwide right to use the spokesperson’s name and approved image in various media. The agreement provided for cash compensation, which was paid in 2011, and royalties based on units sold for the term of the agreement and an additional 12 months thereafter. The agreement expired in June 2012.
	The agreement also granted warrants to purchase 3,000 shares of common stock, 2,000 of which were granted upon signing of the agreement and 1,000 of which were granted in December 2011. The warrants had a term of two years with an exercise price of $50.00 per share. The warrants further provided that in the event (a) the trading price of the common stock of the Company on its principal trading market does not exceed $100.00 within two years of grant and (b) the warrants are not exercised prior to such time, then the spokesperson shall have the right to sell any unexercised portion of the warrants to the Company in exchange for $50.00 for each share of common stock underlying the unexercised portion of the warrants. During 2013, all 3,000 warrants expired and a total liability of $150 was included in accrued expenses. For the year ended December 31, 2013, selling, general and administrative expenses included a mark-to-market loss of $28 related to the warrants issued to the celebrity spokesperson in 2011.
	Supply Agreement
	On July 18, 2014, the Company entered into the First Amended and Restated Exclusive Supply Agreement (the “Agreement”) with DIL. Pursuant to the Agreement, DIL will manufacture and supply Fortetropin exclusively to the Company and may not manufacture Fortetropin for other entities in exchange the Company will purchase minimum quantities of Fortetropin at fixed prices through 2016. In addition, DIL agreed to assign its United States patent application for the manufacture of the formula to the Company and the Company agreed, for a period of seven years from the expiration of the Agreement, it will pay DIL a low single-digit royalty payment for each kilogram of Fortetropin produced by the Company, subject to certain minimum and maximum amounts. DIL also granted the Company a right of first refusal to license and/or acquire the European patent it owns for the manufacture of the formula. The Agreement expires on December 31, 2016, and may be renewed for additional one-year periods unless terminated by either party by giving ninety days’ notice before the expiration of the current term. Included in prepaid expenses and other current assets at December 31, 2014 were payments of $664 that the Company paid in advance for 2014 inventory purchases yet to be delivered by DIL. The minimum purchase obligations under the agreement are approximately $2,394 in 2015 (includes $293 of 2014 purchase commitments that were not yet made) and $2,101 in 2016. The Company did not meet the minimum purchase requirements during the fourth quarter of 2014 and does not expect to meet such requirements for the first quarter of 2015. Under the terms of the agreement with DIL, DIL can terminate the agreement upon written notice to the Company of a material breach. The failure to meet the minimum purchase commitments could be considered a material breach. Upon receipt of such notification, the Company has sixty days to fulfill the purchase requirements.
	Product Liability
	As a manufacturer of nutritional supplements that are ingested by consumers, the Company may be subject to various product liability claims. Although we have not had any claims to date, it is possible that future product liability claims could have a material adverse effect on our business or financial condition, results of operations or cash flows. The Company currently maintains products liability insurance of $5 million per-occurrence and a $10 million annual aggregate coverage. At December 31, 2014, the Company had not recorded any accruals for product liability claims.
	Legal Proceedings
	On October 10, 2014 we filed a request for arbitration before the International Chamber of Commerce against Cenegenics asserting various causes of action, including breach of contract. The request sought payment from Cenegenics of approximately $2.72 million, consisting of unpaid invoices for product shipped and received and for unpaid inventory that was produced for Cenegenics pursuant to the distribution agreement but not yet shipped, as well as related costs and expenses. On November 28, 2014, we entered into a settlement agreement with Cenegenics whereby we agreed to withdraw our October 10, 2014 request for arbitration, and in exchange Cenegenics agreed to pay the Company $1.9 million by April 2016, including an aggregate of $300 during the fourth quarter of 2014, and $100 per month from January 2015 through April 2016. As of the date of this filing, Cenegenics has made all scheduled payments under the terms of the settlement agreement. The settlement resolves all of Cenegenics outstanding obligations with respect to the units of product produced by the Company, including units produced but not yet delivered to Cenegenics. Cenegenics also agreed to pay the Company a storage fee for units of product produced by the Company but not delivered to Cenegenics.
	On January 22, 2015, we filed an Order to Show Cause for a Temporary Restraining Order and Preliminary Injunction before the United States District Court of New Jersey to enjoin and restrain MHP from utilizing the name 4D-Tropin and from selling, distributing, advertising, or making know any product using the name 4D-Tropin. Additionally, we filed a Verified Complaint and Jury Demand before the United States District Court of New Jersey against MHP and Gerard Dente, MHP’s CEO, for willful trademark infringement, trademark dilution, and unfair competition, among other federal and state law claims. On March 9, 2015, the parties settled the matter, with MHP agreeing to cease selling or marketing 4D-Tropin within ninety days of the settlement date and the Company dismissing the lawsuit.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of MYOS Corporation and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions between and among its consolidated subsidiary have been eliminated.
Estimates	Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, measurement of allowances for doubtful accounts and inventory reserves, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities.
	The Company currently cannot predict what future sales, if any, will come from the Company's distributors. In addition, the Company plans to launch its direct-to-consumer branded products at the end of the first quarter of 2015. Management's estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts.
Cash & Cash Equivalents	Cash & Cash Equivalents
	As of December 31, 2014 and 2013, the Company had cash of $1,567 and $451, respectively. The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At December 31, 2014 and 2013, the Company had no cash equivalents.
	The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. The balance at times may exceed federally insured limits. At December 31, 2014 and 2013, the Company's uninsured cash balances totaled $1,292 and $197, respectively.
Concentrations of Risk, Significant Customers and Significant Supplier	Concentrations of Risk, Significant Customers and Significant Supplier
	The Company currently sells its products primarily through two distributors, MHP and Cenegenics. Credit risk is concentrated among these customers. The Company monitors economic conditions and performs ongoing credit evaluation of its customers. Management regularly reviews accounts receivable, and if necessary, establishes an allowance for doubtful accounts that reflects management’s best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Bad debt expense recognized as a result of an allowance for doubtful accounts is classified under selling, general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. If we are unable to collect the outstanding accounts receivable from our distributors, or if our distributors are unable or unwilling to purchase our products and we are unable to secure alternative customers, our operating results and financial condition will be adversely affected.
	Bad debt expense was $390 and $0 for the years ended December 31, 2014 and 2013, respectively. Bad debt expense for the year ended December 31, 2014 related to recording an allowance for doubtful accounts against existing accounts receivable balance of Cenegenics based on management’s best estimate of amounts that may not be collectible.
	At December 31, 2014 and 2013, the Company had the following concentrations of net accounts receivable with customers:
			December 31,			December 31,
			2014			2013
	MHP		$	-		$	645
	Cenegenics			1,372			-
	Subtotal			1,372			645
	Allowance for doubtful accounts			(390	)		-
	Accounts receivable, net		$	982		$	645
	For the years ended December 31, 2014 and 2013, the Company had the following concentrations of revenues with customers:
			Years Ended December 31,
			2014			2013
	MHP			36	%		100	%
	Cenegenics			63	%		0	%
	Other			1	%		0	%
	Total			100	%		100	%
	The Company currently relies on one third-party manufacturer to produce Fortetropin (see Note 12 – Commitments and Contingencies - Supply Agreement). This manufacturer purchases all the needed raw materials from suppliers and coordinates any additional production steps with third-parties. We have multiple vendors for blending, packaging and labeling. The Company is pursuing other supply alternatives.
Inventories, net	Inventories, net
	Inventories are valued at the lower of cost or market, with cost determined on a first in, first-out basis. The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors.
Fixed Assets	Fixed Assets
	Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the Consolidated Statements of Operations and Comprehensive Loss.
	Depreciation is provided using the straight-line method for all fixed assets.
	We review our fixed assets for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. If the assets are determined to be unrecoverable, an impairment loss is calculated by determining the difference between the carrying values and the estimated fair value. Included in the year ended December 31, 2014, was an impairment charge of $5 to reduce the unrecoverable net carrying value of a capitalized fixed asset to zero. We did not consider any of our property and equipment to be impaired during the year ended December 31, 2013.
Intangible Assets	Intangible Assets
	The Company’s intangible assets primarily relate to intellectual property pertaining to Fortetropin, including the MYO-T12 formula, trademarks, trade secrets, patent application and domain names acquired from Peak Wellness, Inc. in February 2011. The intellectual property asset was initially recorded as an indefinite-lived intangible asset and tested annually during the fourth quarter for impairment or more frequently if events or circumstances changed that could potentially reduce the fair value of the asset below its carrying value. In 2011, based on (i) assessment of current and expected future economic conditions, (ii) trends, strategies and projected revenues and (iii) assumptions similar to those that market participants would make in valuing the Company's intangible assets, management determined that the carrying values of the intellectual property asset exceeded its fair value. Accordingly, the Company recorded noncash impairment charges totaling $2,662 and reduced the intellectual property asset to its fair value of $2,000. Management performed annual impairment tests in 2012 and 2013 and determined no further impairment existed. During the second quarter of 2014, management made an assessment and based on expansion into new markets and introduction of new formulas determined that the intellectual property had a finite useful life of ten (10) years and began amortizing the carrying value of the intellectual property asset over its estimated useful life. Management made a separate determination that no further impairment existed at the time. Based on two consecutive quarters of minimal revenues combined with our history of operating losses, we tested the intellectual property asset for impairment again in the fourth quarter of 2014 and determined that the asset value was recoverable and therefore, no impairment loss was recognized.
	Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows, selection of the appropriate discount rate to measure the risk inherent in future cash flow streams, assessment of an asset’s life cycle, competitive trends impacting the asset as well as other factors. Changes in these underlying assumptions could significantly impact the asset’s estimated fair value.
	In July 2014, the Company acquired the United States patent application for the manufacture of Fortetropin from Deutsches Institut fur Lebensmitteltechnik e.V. - the German Institute for Food Technologies (“DIL”). The cost of the patent application, which was capitalized as an intangible asset, was determined to be $101, based on the present value of the minimum guaranteed royalty payable to DIL using a discount rate of 10%. The intangible asset will be amortized over an estimated useful life of ten (10) years. The remaining contingent royalty payments will be recorded as the contingency is resolved and the royalty becomes payable under the arrangement. For additional information on the amended supply agreement with DIL refer to “Note 12 – Commitments and Contingencies - Supply Agreement.”
	Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor’s patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years.
	Intangible assets at December 31, 2014 and December 31, 2013 consisted of the following:
	(In thousand $)		December 31,			December 31,
			2014			2013
	Intangibles with finite lives:
	Intellectual property		$	2,101		$	-
	Less:  accumulated amortization			(155	)		-
	Total intangibles with finite lives:			1,946			-
	Intangibles with indefinite lives:
	Intellectual property			-			2,000
	Patent costs			44			38
	Total intangibles with indefinite lives:			44			2,038
	Total intangible assets, net		$	1,990		$	2,038
	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense for intangible assets is estimated to be $210 in each of the next five years.
Revenue Recognition	Revenue Recognition
	The Company records revenue when persuasive evidence of an arrangement exists, product has been shipped or delivered, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Depending on individual customer agreements, sales are recognized either upon shipment of product to customers or upon delivery. The Company’s gross product sales may be subject to sales allowances and deductions in arriving at reported net product sales. Reductions from gross sales for customer discounts and rebates have been minimal, and sales allowances for product returns have not been provided, since under our existing arrangements, customers are not permitted to return product except for non-conforming product.
Research and Development	Research and Development
	Research and development expenses consist primarily of salaries, benefits, and other related costs, including stock-based compensation, for personnel serving in our research and development functions, and other internal operating expenses, the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed.
Advertising	Advertising
	The Company charges the costs of advertising to selling, general and administrative expense as incurred. Advertising and promotional costs, which consist primarily of co-operative advertising fees payable to MHP, were $732 and $1,659 for the years ended December 31, 2014 and 2013, respectively. Pursuant to our distribution agreement with MHP, the Company has a co-operative advertising arrangement whereby the Company pays MHP a fee for each unit sold.
Shipping and Handling Costs	Shipping and Handling Costs
	The Company records costs of shipping product to our distributors in cost of sales. These expenses were $10 and $0 for the years ended December 31, 2014 and 2013, respectively.
Foreign Currency	Foreign Currency
	Our revenues are generated in U.S. dollars, while a significant portion of our expenses may be incurred in foreign currencies, principally the payments to our primary manufacturer that are paid in euros. Foreign currency gains resulting from transactions denominated in a currency other than the functional currency were $42 and $0 for the years ended December 31, 2014 and 2013, respectively, and are included in selling, general and administrative expense, net in the accompanying consolidated statements of operations.
Share Based Compensation	Stock-based Compensation
	Generally, stock-based payments are measured at their estimated fair value on the date of grant. Stock-based awards to non-employees are re-measured at fair value each financial reporting date until performance is complete. Stock-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period.
	The Company uses the Black-Scholes option-pricing model to estimate the fair value of options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
	Stock-based compensation expense for awards to employees and non-employees was $1,691 and $1,335 for the years ended December 31, 2014 and 2013, respectively.
Comprehensive Loss	Comprehensive Loss
	Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by, or distributions to, the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that are included in comprehensive income (loss), but excluded from net loss as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company had no other comprehensive income (loss) items for the years ended December 31, 2014 and 2013. Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.
Segment Information	Segment Information
	Accounting Standards Codification (“ASC”) 280, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information about operating segments and requires selected information for those segments to be presented in the financial statements. It also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. Management has determined that the Company operates in one segment.
Fair Value Measurement	Fair Value Measurement
	Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level.
	The following are the hierarchy levels of inputs to measure fair value:
		Level 1:	Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.
		Level 2:	Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active.
		Level 3:	Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity.
	A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At December 31, 2014 and 2013, the Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. Due to their short-term nature, the carrying amounts of the Company’s financial instruments approximated their fair values.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share
	Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the “treasury stock” method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the years ended December 31, 2014 and 2013, the Company incurred a net loss. Accordingly, the Company’s common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at December 31, 2014 and 2013 but excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,541,330 and 232,320, respectively.
Income Taxes	Income Taxes
	Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized.
	The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement. This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions. The Company has no uncertain income tax positions.
	Interest costs and penalties related to income taxes are classified as interest expense and operating expenses, respectively, in the Company's financial statements. For the years ended December 31, 2014 and 2013, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.
Reclassifications	Reclassifications
	The Company has revised the presentation of “Selling, General and Administrative Expenses” within the Consolidated Statements of Operations for the year ended December 31, 2013 to conform to the current year presentation. Research and development expenses of $754 for the year ended December 31, 2013, were previously not presented separately. This reclassification was for presentation purposes and had no effect on the financial position, results of operations, or cash flows for the period presented.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Concentration Risk [Line Items]
Summary of Intangible Assets	(In thousand $)	December 31,			December 31,
		2014			2013
	Intangibles with finite lives:
	Intellectual property	$	2,101		$	-
	Less:  accumulated amortization		(155	)		-
	Total intangibles with finite lives:		1,946			-
	Intangibles with indefinite lives:
	Intellectual property		-			2,000
	Patent costs		44			38
	Total intangibles with indefinite lives:		44			2,038
	Total intangible assets, net	$	1,990		$	2,038
Accounts receivable [Member]
Concentration Risk [Line Items]
Schedule of concentrations of net accounts receivable with customers		December 31,			December 31,
		2014			2013
	MHP	$	-		$	645
	Cenegenics		1,372			-
	Subtotal		1,372			645
	Allowance for doubtful accounts		(390	)		-
	Accounts receivable, net	$	982		$	645
Revenues [Member]
Concentration Risk [Line Items]
Summary of concentrations risk with customers		Years Ended December 31,
		2014			2013
	MHP		36	%		100	%
	Cenegenics		63	%		0	%
	Other		1	%		0	%
	Total		100	%		100	%

Inventories_Net_Tables

Inventories, Net (Tables)	12 Months Ended
	Dec. 31, 2014
Inventories, Net [Abstract]
Summary of Inventory	(In thousand $)	December 31,			December 31,
		2014			2013
	Raw materials	$	1,638		$	137
	Work in process		2			-
	Finished goods		443			6
			2,083			143
	Less: inventory reserves		(269	)		-
	Inventories, net	$	1,814		$	143

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Fixed Assets [Abstract]
Schedule of fixed assets	(In thousand $)	December 31,			December 31,
		2014			2013
	Furniture, fixtures and equipment	$	134		$	127
	Computers and software		21			17
	Leasehold improvements		239			234
	Other		7			5
	Total fixed assets		401			383
	Less: accumulated depreciation		(88	)		(39	)
	Net book value of fixed assets	$	313		$	344

Prepaid_Expenses_Other_Current1

Prepaid Expenses, Other Current Assets and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Prepaid Expenses, Other Current Assets and Accrued Expenses [Abstract]
Summary of prepaid expenses and other current assets	(In thousand $)	December 31,		December 31,
		2014		2013
	Prepaid insurance	$	46	$	63
	Prepaid research and development		15		-
	Prepaid stock compensation		-		70
	Prepaid consulting		8		20
	Prepaid inventory purchases		664		-
	Other		12		62
	Total prepaid expenses and other current assets	$	745	$	215
Summary of accrued expenses	(In thousand $)	December 31,		December 31,
		2014		2013
	Advertising and promotional expense payable	$	171	$	171
	Audit fees payable		25		35
	Rent payable		30		30
	Research & development		49		-
	Accrued salaries & bonuses		92		-
	Consulting fees payable		96		65
	Other accrued expenses		32		11
	Total accrued expenses	$	495	$	312

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity [Abstract]
Schedule of periodical gross proceeds from private placements
	(In thousand $)
					Gross
	Date		Shares		Proceeds
	25-Feb-11			95,334	$	1,430
	31-May-11			28,200		423
	27-Jun-11			37,500		563
	12-Jul-11			1,667		25
	2-Dec-11			4,000		40
	10-Feb-12			65,000		325
	14-Feb-12			80,000		400
	7-Mar-12			20,000		100
	15-Mar-12			35,000		175
	22-Mar-12			5,000		25
	9-Apr-12			20,000		100
	24-Apr-12	*		4,000		-
	28-Jun-12			48,000		600
	6-Jul-12			411,600		5,145
	27-Jan-14			631,346		4,735
	19-Nov-14			193,865		1,816
				1,680,512	$	15,902
	* Shares issued under price protection agreement

Warrants_Tables

Warrants (Tables) (Warrants [Member])	12 Months Ended
	Dec. 31, 2014
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of warrants issued to private placement				Number of				Shares Underlying		Shares Underlying		Shares Underlying
				Shares				Warrants		Warrants		Warrants
				Underlying				Exchanged,		Outstanding		Exercisable at					Expiration
				Warrants				Exercised		at December,		December 31,		Exercise			Term in
	Description	Grant Date		Granted				or Expired		2014		2014		Price			Years
	Series A	27-Jan-14			315,676				-		315,676		315,676	$	15			2.08
	Series B	27-Jan-14			157,846				-		157,846		157,846	$	45			4.07
	Series C	19-Nov-14			145,399				-		145,399		-	$	12			5.38
	Series D	19-Nov-14			193,865				-		193,865		193,865	$	9.37			0.38
	Series E	19-Nov-14			145,399				-		145,399		-	$	15			7.38
					958,185				-		958,185		667,387
Summary of warrants activities						Weighted
		Shares				Average
		Underlying				Exercise
		Warrants				Price
	Balance at December 31, 2012		3,000			$	50
	Warrants granted		-				-
	Warrants exercised		-				-
	Warrants cancelled/exchanged/expired		(3,000	)			50
	Balance at December 31, 2013		-			$	-
	Warrants granted		958,185				18.35
	Warrants exercised		-				-
	Warrants cancelled/exchanged/expired		-				-
	Balance at December 31, 2014		958,185			$	18.35
Summary of assumptions used to value warrants using Black-Scholes option pricing model
				Number of Shares				Stock
				Underlying				Price on
				Warrants				Measurement		Exercise		Expected		Expected			Dividend			Risk Free
	Description	Grant Date		Granted				Date		Price		Term		Volatility			Yield			Rate
	Series A	1/27/2014			315,676			$	7	$	15		3		150	%		0	%		0.76	%
	Series B	1/27/2014			157,846			$	7	$	45		5		150	%		0	%		1.61	%
	Series C	11/19/2014			145,399			$	9.37	$	12		5.5		94.6	%		0	%		1.64	%
	Series D	11/19/2014			193,865			$	9.37	$	9.37		0.5		93.44	%		0	%		0.07	%
	Series E	11/19/2014			145,399			$	9.37	$	15		7.5		94.6	%		0	%		1.64	%
					958,185
Summary of assumptions used to to estimate fair value of Make-Whole Shares	Volatility		95	%
	Risk-Free Interest Rate		1.47	%
	Expected Term in Years		1.00 years
	Dividend Rate		0	%
	Fair Value of Common Stock Share	$	9.37

Stock_Compensation_Tables

Stock Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of restricted stock award activities							Weighted
							Average
							Grant Date
			Shares				Share Price
	Restricted stock awards unvested at December 31, 2012			35,700			$	16.21
	Granted			26,780				7.39
	Vested			(30,030	)			9.7
	Forfeited			-				-
	Restricted stock awards unvested at December 31, 2013			32,450			$	14.96
	Granted			13,200				7.79
	Vested			(13,450	)			13.86
	Forfeited			(10,000	)			7
	Restricted stock awards unvested at December 31, 2014			22,200			$	14.95
Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of stock option activities											Weighted
							Weighted				Average
			Shares				Average				Remaining
			Under				Exercise				Contractual
			Options				Price				Term (Years)
	Balance at December 31, 2012			30,160			$	26.58
	Options granted			202,200			$	14.58
	Options exercised			-
	Options forfeited			(40	)		$	10
	Balance at December 31, 2013			232,320			$	16.14				8.98
	Options granted			146,560				11.83
	Options exercised			-				-
	Options cancelled/forfeited			(11,800	)			8.09
	Balance at December 31, 2014			367,080			$	14.68				8.5
Summary of assumptions used to value stock options granted using a Black-Scholes model			2014				2013
	Risk-free interest rate			1.63%-2.84%				1.80%-2.89%
	Expected volatility			145%-151%				152%-166%
	Weighted average expected volatility			148	%			163	%
	Expected term (years)			5.63-10.0				10
	Expected dividend yield			0	%			0	%
Summary of option outstanding and exercisable	Options Outstanding												Options Exercisable
									Weighted Average								Weighted Average
	Range of				Options				Remaining				Range of		Options		Remaining
	Exercise Price				Outstanding				Contractual Life				Exercise Price		Exercisable		Contractual Life
	$	7				5,000				7.39			$	7		5,000		7.39
	$	8.6				30,500				9.2			$	8.6		7,625		9.2
	$	10				9,320				8.06			$	10		7,653		8.06
	$	11				3,000				8.03			$	11		1,500		8.03
	$	12.1				30,500				9.36			$	12.1		7,625		9.36
	$	12.5				106,200				8.46			$	12.5		58,509		8.43
	$	12.55				20,000				9.39			$	12.55		-		-
	$	13				14,600				9.53			$	13		3,650		9.53
	$	13.45				2,000				9.48			$	13.45		-		-
	$	13.5				14,960				9.49			$	13.5		-		-
	$	13.75				6,000				9.68			$	13.75		-		-
	$	17.5				100,000				8.11			$	17.5		50,000		8.11
	$	22.5				5,000				6.62			$	22.5		5,000		6.62
	$	32				15,000				6.53			$	32		15,000		6.53
	$	34.5				5,000				6.56			$	34.5		5,000		6.56
						367,080										166,562
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock-based compensation			2014				2013
	Cost of sales		$	-			$	-
	Research and development			123				8
	Selling, general and administrative			1,568				1,327
	Total stock-based compensation		$	1,691			$	1,335

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Summary of future minimum lease payments under the non-cancelable operating lease	(In thousand $)
	Years Ended December 31,	Amount
	2015	$	150
	2016		152
	2017		181
	2018		187
	2019		191
	Total	$	861

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Summary of income tax expense	(In thousand $)
	Years ended December 31,	2014			2013
	Current provision	$	(748	)	$	-
	Deferred provision		-			-
	Total tax provision (benefit)	$	(748	)	$	-
Deferred tax assets and liabilities	(In thousand $)	2014			2013
	Federal net operating losses	$	3,997		$	3,042
	State net operating losses		160			531
	Stock options		1,104			-
	Federal tax credit		110			-
	Amortization		508			560
	Depreciation		(12	)		(16	)
	Contributions		13			4
	Total gross deferred tax assets/(liabilities)	$	5,880		$	4,121
	Less valuation allowance		(5,880	)		(4,121	)
	Net deferred tax assets/(liabilities)	$	-		$	-
Statutory federal income tax rate and the effective rate reconciliation	(In thousand $)	2014			2013
		($)			($)
	Federal statutory rate	$	(1,770	)	$	(1,450	)
	Sale of NJ NOL/credits		(495	)		-
	Permanent differences		136			50
	Research and development		(110	)		-
	State taxes		1			-
	Stock compensation		(584	)		-
	Valuation allowance		2,074			1,400
	Effective tax rate	$	(748	)	$	-

Nature_of_Operations_Basis_of_1

Nature of Operations, Basis of Presentation and Liquidity (Details) (USD $)	12 Months Ended		93 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2012
Nature of Operations and Basis of Presentation (Textual)
Cash to meet current obligations	$1,567	$451	$1,567	$3,980
Working Capital	4,534		4,534
Current assets	5,108	1,454	5,108
Current liabilities	574	496	574
Net loss	-4,459	-4,263
Net cash used in operating activities	-5,089	-3,154
Accumulated deficit	18,367	13,908	18,367
Revenue	3,343	3,318	7,672
Net cash provided by financing activities	$6,234		$15,345

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of concentrations of net accounts receivable with customers
Subtotal	$1,372	$645
Allowance for doubtful accounts	-390
Accounts receivable, net	982	645
Maximum Human Performance [Member]
Summary of concentrations of net accounts receivable with customers
Subtotal		645
Cenegenics [Member]
Summary of concentrations of net accounts receivable with customers
Subtotal	$1,372

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (Sales Revenue, Net [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Concentration Risk [Line Items]
Total Concentration Risk, Percentage Total	100.00%	100.00%
Maximum Human Performance [Member]
Concentration Risk [Line Items]
Total Concentration Risk, Percentage Total	36.00%	100.00%
Cenegenics [Member]
Concentration Risk [Line Items]
Total Concentration Risk, Percentage Total	63.00%	0.00%
Other One [Member]
Concentration Risk [Line Items]
Total Concentration Risk, Percentage Total	1.00%	0.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Intangibles with finite lives:
Intellectual property	$2,101
Less: accumulated amortization	-155
Total intangibles with finite lives:	1,946
Intangibles with indefinite lives:
Total intangibles with indefinite lives:	44	2,038
Total intangible assets, net	1,990	2,038
Intellectual Property [Member]
Intangibles with indefinite lives:
Total intangibles with indefinite lives:		2,000
Patents [Member]
Intangibles with indefinite lives:
Total intangibles with indefinite lives:	$44	$38

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Summary of Significant Accounting Policies (Textual)
Cash	$1,567	$451
Cash, uninsured amount	1,292	197
Cash equivalents
Bad debt expense	390
Estimated useful lives of fixed assets	3 to 7 years.
Fixed assets impairment charge	5
Noncash impairment charges of intangible assets	2,662
Intellectual property asset, fair value	2,000
Intangible asset acquired	101
Discount Rate	10.00%
Amortization expense for intangible assets year one	210
Amortization expense for intangible assets, year two	210
Amortization expense for intangible assets, year three	210
Amortization expense for intangible assets, year four	210
Amortization expense for intangible assets, year five	210
Advertising and promotional cost incurred	732	1,659
Shipping and handling costs	10	0
Share-based compensation expense	1,691	1,335
Anti-dilutive excluded from diluted net loss per share computation	1,541,330	232,320
Research and Development Expense	1,348	754
Foreign currency gains resulting from transactions	$42	$0
Patents [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets	20 years
Intellectual Property [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets	10 years

Inventories_Net_Details

Inventories, Net (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of Inventory
Raw materials	$1,638	$137
Work in process	2
Finished goods	443	6
Inventories, gross	2,083	143
Less: inventory reserves	-269
Inventories, net	$1,814	$143

Inventories_Net_Details_Textua

Inventories, Net (Details Textuals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory, Net (Textual)
Inventory reserves	$269

Fixed_Assets_Details

Fixed Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment, Gross
Total fixed assets	$401	$383
Less: accumulated depreciation	-88	-39
Net book value of fixed assets	313	344
Furniture, fixtures and equipment [Member]
Property, Plant and Equipment, Gross
Total fixed assets	134	127
Computers and software [Member]
Property, Plant and Equipment, Gross
Total fixed assets	21	17
Leasehold improvements [Member]
Property, Plant and Equipment, Gross
Total fixed assets	239	234
Other [Member]
Property, Plant and Equipment, Gross
Total fixed assets	$7	$5

Fixed_Assets_Details_Textuals

Fixed Assets (Details Textuals) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fixed Assets (Textual)
Depreciation expense	$49	$37

Debt_Details_Textual

Debt (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Debt (Textual)
Debt aggregate principal amount	$500
Debt disbursement at a per annum interest rate	prime rate plus 1.25
Total outstanding balance

Prepaid_Expenses_Other_Current2

Prepaid Expenses, Other Current Assets and Accrued Expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of prepaid expenses and other current assets
Prepaid insurance	$46	$63
Prepaid research and development	15
Prepaid stock compensation		70
Prepaid consulting	8	20
Prepaid inventory purchases	664
Other	12	62
Total prepaid expenses and other current assets	$745	$215

Prepaid_Expenses_Other_Current3

Prepaid Expenses, Other Current Assets and Accrued Expenses (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of accrued liabilities
Advertising and promotional expense payable	$171	$171
Audit fees payable	25	35
Rent payable	30	30
Research & development	49
Accrued salaries & bonuses	92
Consulting fees payable	96	65
Other accrued expenses	32	11
Total accrued expenses	$495	$312

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Shares	3,103,300	2,227,447
Gross Proceeds	$6,234
February 25, 2011 [Member]
Class of Stock [Line Items]
Shares	95,334
Gross Proceeds	1,430
May 31, 2011 [Member]
Class of Stock [Line Items]
Shares	28,200
Gross Proceeds	423
June 27, 2011 [Member]
Class of Stock [Line Items]
Shares	37,500
Gross Proceeds	563
July 12, 2011 [Member]
Class of Stock [Line Items]
Shares	1,667
Gross Proceeds	25
December 2, 2011 [Member]
Class of Stock [Line Items]
Shares	4,000
Gross Proceeds	40
February 10, 2012 [Member]
Class of Stock [Line Items]
Shares	65,000
Gross Proceeds	325
February 14, 2012 [Member]
Class of Stock [Line Items]
Shares	80,000
Gross Proceeds	400
March 7, 2012 [Member]
Class of Stock [Line Items]
Shares	20,000
Gross Proceeds	100
March 15, 2012 [Member]
Class of Stock [Line Items]
Shares	35,000
Gross Proceeds	175
March 22, 2012 [Member]
Class of Stock [Line Items]
Shares	5,000
Gross Proceeds	25
April 9, 2012 [Member]
Class of Stock [Line Items]
Shares	20,000
Gross Proceeds	100
April 24, 2012 [Member]
Class of Stock [Line Items]
Shares	4,000
Gross Proceeds
June 28, 2012 [Member]
Class of Stock [Line Items]
Shares	48,000
Gross Proceeds	600
July 6, 2012 [Member]
Class of Stock [Line Items]
Shares	411,600
Gross Proceeds	5,145
January 27, 2014 [Member]
Class of Stock [Line Items]
Shares	631,346
Gross Proceeds	4,735
November 19, 2014 [Member]
Class of Stock [Line Items]
Shares	193,865
Gross Proceeds	$1,816

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Feb. 05, 2014	Jan. 31, 2014	Dec. 31, 2014	Nov. 30, 2014	Dec. 22, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Reverse stock split shares outstanding and authorized shares of common stock and preferred stock ratio	1 for 50
Common stock, shares authorized	300,000,000		8,000,000		8,000,000	6,000,000
Preferred stock, shares authorized	25,000,000		500,000			500,000
Common stock, shares issued			3,103,300			2,227,447
Purchase of series A common stock by warrants granted		315,676
Purchase of series B common stock by warrants granted		157,846
Gross Proceeds			$15,900
Proceeds from issuance of common stock			6,234
Shares issued for private placement fee		355
Percentage of common stock issued for fee		7.50%
Private placement offering, net of issuance cost
Additional share issued		631,346
February 25, 2011 [Member]
Class of Stock [Line Items]
Common stock, shares issued			95,334
Proceeds from issuance of common stock			1,430
Private placement offering, net of issuance cost		4,663
Additional share issued		47,351
Public Offering [Member]
Class of Stock [Line Items]
Common stock, description				(i) one share of our common stock; (ii) one Series C common stock warrant to purchase 0.75 shares of our common stock; (iii) one Series D common stock warrant to purchase one share of our common stock; and, (iv) one Series E common stock warrant to purchase 0.75 shares of our common stock, at a public offering price of $9.37 per unit
Additional share issued				193,865
January 27, 2014 [Member]
Class of Stock [Line Items]
Common stock, shares issued			631,346
Proceeds from issuance of common stock			4,735
November 19, 2014 [Member]
Class of Stock [Line Items]
Common stock, shares issued			193,865
Proceeds from issuance of common stock			1,816
Maximum [Member]
Class of Stock [Line Items]
Common stock price, per share				14.06
Common Stock [Member]
Class of Stock [Line Items]
Proceeds from issuance of common stock			1
Private placement offering, net of issuance cost			$1,571
Additional share issued			825,211
Series B Warrants [Member]
Class of Stock [Line Items]
Term of warrants		5 years
Warrants exercise price		$45
Series A Warrants [Member]
Class of Stock [Line Items]
Term of warrants		3 years
Warrants exercise price		$15
Series C Warrants [Member] | Public Offering [Member]
Class of Stock [Line Items]
Warrants exercise price				12
Series D Warrants [Member] | Public Offering [Member]
Class of Stock [Line Items]
Warrants exercise price				9.37
Common stock price, per share				12
Warrants expiration, description				Each Series D warrant has an exercise price of $9.37 per share, is immediately exercisable and separately transferable from the shares, may be redeemed by us in the event that the closing price of our stock is $12.00 or above for 20 consecutive trading days
Series E Warrants [Member] | Public Offering [Member]
Class of Stock [Line Items]
Warrants exercise price				15
Warrants expiration, description				Each Series E warrant is exercisable only if the Series D warrants are exercised, has an exercise price of $15.00 per share, is exercisable subsequent to the six month anniversary of the date of issuance and separately transferable from the shares and expire on the 90-month anniversary of the date of issuance.
Percentage of gross proceeds from investors				3.50%
Percentage of placement fee				7.00%

Warrants_Details

Warrants (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Summary of warrants issued to private placement stockholders and consultants
Number of Shares Underlying Warrants Granted	6,000
Shares Under Warrants Outstanding at December, 2014	339,880
Shares Under Warrants Exercisable at December, 2014	166,562
Exercise Price	$13.75
Series A Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	27-Jan-14
Number of Shares Underlying Warrants Granted	315,676
Shares Underlying Warrants Exchanged, Exercised or Expired
Shares Under Warrants Outstanding at December, 2014	315,676
Shares Under Warrants Exercisable at December, 2014	315,676
Exercise Price	$15
Expiration Term in Years	2 years 29 days
Series B Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	27-Jan-14
Number of Shares Underlying Warrants Granted	157,846
Shares Underlying Warrants Exchanged, Exercised or Expired
Shares Under Warrants Outstanding at December, 2014	157,846
Shares Under Warrants Exercisable at December, 2014	157,846
Exercise Price	$45
Expiration Term in Years	4 years 26 days
Series C Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	19-Nov-14
Number of Shares Underlying Warrants Granted	145,399
Shares Underlying Warrants Exchanged, Exercised or Expired
Shares Under Warrants Outstanding at December, 2014	145,399
Shares Under Warrants Exercisable at December, 2014
Exercise Price	$12
Expiration Term in Years	5 years 4 months 17 days
Series D Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	19-Nov-14
Number of Shares Underlying Warrants Granted	193,865
Shares Underlying Warrants Exchanged, Exercised or Expired
Shares Under Warrants Outstanding at December, 2014	193,865
Shares Under Warrants Exercisable at December, 2014	193,865
Exercise Price	$9.37
Expiration Term in Years	4 months 17 days
Series E Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	19-Nov-14
Number of Shares Underlying Warrants Granted	145,399
Shares Underlying Warrants Exchanged, Exercised or Expired
Shares Under Warrants Outstanding at December, 2014	145,399
Shares Under Warrants Exercisable at December, 2014
Exercise Price	$15
Expiration Term in Years	7 years 4 months 17 days
Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Shares Underlying Warrants Granted	958,185
Shares Underlying Warrants Exchanged, Exercised or Expired
Shares Under Warrants Outstanding at December, 2014	958,185
Shares Under Warrants Exercisable at December, 2014	667,387
Exercise Price	$18.35

Warrants_Details_1

Warrants (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary of activity in warrants
Number of Shares Underlying Warrants Granted	6,000
Balance, Shares Underlying Options/Warrants	339,880
Warrants/Options granted, Weighted Average Exercise Price	$13.75
Warrants [Member]
Summary of activity in warrants
Number of Shares Underlying Warrants Granted	958,185
Options/Warrants exercised, Share Under Options/Warrants
Options/Warrants cancelled/expired, Shares Underlying Options/Warrants		-3,000
Balance, Shares Underlying Options/Warrants	958,185
Beginning Balance, Weighted Average Exercise Price		$50
Warrants/Options granted, Weighted Average Exercise Price	$18.35
Warrants/Options cancelled/expired, Weighted Average Exercise Price		$50
Balance, Weighted Average Exercise Price	$18.35

Warrants_Details_2

Warrants (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	6,000
Exercise Price	$13.75
Expected Term	5 years 7 months 17 days
Expected Volatility	151.00%
Dividend Yield	0.00%
Risk Free Rate	1.63%
Warrants [Member]
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	958,185
Exercise Price	$18.35
Expected Term	1 year
Expected Volatility	95.00%
Dividend Yield	0.00%
Risk Free Rate	1.47%
Warrants [Member] | Series A January 27, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	315,676
Stock Price on Measurement Date	$7
Exercise Price	$15
Expected Term	3 years
Expected Volatility	150.00%
Dividend Yield	0.00%
Risk Free Rate	0.76%
Warrants [Member] | Series B January 27, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	157,846
Stock Price on Measurement Date	$7
Exercise Price	$45
Expected Term	5 years
Expected Volatility	150.00%
Dividend Yield	0.00%
Risk Free Rate	1.61%
Warrants [Member] | Series C November 19, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	145,399
Stock Price on Measurement Date	$9.37
Exercise Price	$12
Expected Term	5 years 6 months
Expected Volatility	94.60%
Dividend Yield	0.00%
Risk Free Rate	1.64%
Warrants [Member] | Series D November 19, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	193,865
Stock Price on Measurement Date	$9.37
Exercise Price	$9.37
Expected Term	6 months
Expected Volatility	93.44%
Dividend Yield	0.00%
Risk Free Rate	0.07%
Warrants [Member] | Series E November 19, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	145,399
Stock Price on Measurement Date	$9.37
Exercise Price	$15
Expected Term	7 years 6 months
Expected Volatility	94.60%
Dividend Yield	0.00%
Risk Free Rate	1.64%

Warrants_Details_3

Warrants (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2014
Assumptions used to estimate fair value of Make-Whole Shares
Volatility	151.00%
Risk-Free Interest Rate	1.63%
Expected Term in Years	5 years 7 months 17 days
Dividend Rate	0.00%
Warrant [Member]
Assumptions used to estimate fair value of Make-Whole Shares
Volatility	95.00%
Risk-Free Interest Rate	1.47%
Expected Term in Years	1 year
Dividend Rate	0.00%
Fair Value of Common Stock Share	9.37

Warrants_Details_Textual

Warrants (Details Textual) (USD $)	1 Months Ended	12 Months Ended		0 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Nov. 19, 2014	Nov. 30, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		6,000
Exercise Price		$13.75
Derivative liability related to warrants			$28
Expected Term		5 years 7 months 17 days
Estimated fair value of warrants		2,486		1,049
Additional share issued	631,346
Public Offering [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Granted				484,663
Additional share issued					193,865
Maximum [Member]
Warrants (Textual)
Common stock price, per share					14.06
Warrant [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Granted		958,185
Exercise Price		$18.35
Expected Term		1 year
Warrant [Member] | Series A January 27, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		315,676
Exercise Price		$15
Expected Term		3 years
Warrant [Member] | Series B January 27, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		157,846
Exercise Price		$45
Expected Term		5 years
Warrant [Member] | Series C November 19, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		145,399
Exercise Price		$12
Expected Term		5 years 6 months
Estimated fair value of warrants		969
Warrants holders entitle to purchase shares of common stock period, Description		66-months
Warrant [Member] | Series D November 19, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		193,865
Exercise Price		$9.37
Expected Term		6 months
Estimated fair value of warrants		470
Warrants holders entitle to purchase shares of common stock period, Description		6-months
Warrant [Member] | Series E November 19, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		145,399
Exercise Price		$15
Expected Term		7 years 6 months
Estimated fair value of warrants		$1,048
Warrants holders entitle to purchase shares of common stock period, Description		90-months

Stock_Compensation_Details

Stock Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Warrants/Options granted, Shares Underlying Warrants/Options	6,000
Balance, Shares Underlying Options/Warrants	339,880
Warrants/Options granted, Weighted Average Exercise Price	$13.75
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	7 years 7 months 21 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning Balance, Shares Underlying Options/Warrants	232,320	30,160
Warrants/Options granted, Shares Underlying Warrants/Options	146,560	202,200
Options/Warrants exercised, Share Underlying Options/Warrants
Options/Warrants forfeited/expired, Shares Underlying Options/Warrants	-11,800	-40
Balance, Shares Underlying Options/Warrants	367,080	232,320
Beginning Balance, Weighted Average Exercise Price	$16.14	$26.58
Warrants/Options granted, Weighted Average Exercise Price	$11.83	$14.58
Warrants/Options exercised, Weighted Average Exercise Price
Warrants/Options cancelled/forfeited, Weighted Average Exercise Price	$8.09	$10
Balance, Weighted Average Exercise Price	$14.68	$16.14
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	8 years 6 months	8 years 11 months 23 days

Stock_Compensation_Details_1

Stock Compensation (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Assumption used to value options using Black-scholes model
Risk-free interest rate	1.63%
Expected Volatility	151.00%
Expected term (years)	5 years 7 months 17 days
Expected dividend yield	0.00%
Stock Options [Member]
Assumption used to value options using Black-scholes model
Weighted average expected volatility	148.00%	163.00%
Expected term (years)		10 years
Expected dividend yield	0.00%	0.00%
Maximum [Member] | Stock Options [Member]
Assumption used to value options using Black-scholes model
Risk-free interest rate	2.84%	2.89%
Expected Volatility	151.00%	166.00%
Expected term (years)	10 years
Minimum [Member] | Stock Options [Member]
Assumption used to value options using Black-scholes model
Risk-free interest rate	1.63%	1.80%
Expected Volatility	145.00%	152.00%
Expected term (years)	5 years 7 months 17 days

Stock_Compensation_Details_2

Stock Compensation (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$7
Options outstanding	339,880
Options Granted, Weighted Average Remaining Contractual Life	7 years 7 months 21 days
Options Exercisable	166,562
$ 7.00 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$7
Options outstanding	5,000
Options Granted, Weighted Average Remaining Contractual Life	7 years 4 months 21 days
Options exercisable, Range of Exercise Price	$7
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 4 months 21 days
$ 8.60 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$8.60
Options outstanding	30,500
Options Granted, Weighted Average Remaining Contractual Life	9 years 2 months 12 days
Options exercisable, Range of Exercise Price	$8.60
Options Exercisable	7,625
Options Exercisable, Weighted Average Remaining Contractual Life	9 years 2 months 12 days
$ 10.00 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$10
Options outstanding	12,120
Options Granted, Weighted Average Remaining Contractual Life	8 years 22 days
Options exercisable, Range of Exercise Price	$10
Options Exercisable	7,653
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 22 days
$ 11.00 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$11
Options outstanding	3,000
Options Granted, Weighted Average Remaining Contractual Life	8 years 11 days
Options exercisable, Range of Exercise Price	$11
Options Exercisable	1,500
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 11 days
$ 12.10 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$12.10
Options outstanding	30,500
Options Granted, Weighted Average Remaining Contractual Life	9 years 4 months 10 days
Options exercisable, Range of Exercise Price	$12.10
Options Exercisable	7,625
Options Exercisable, Weighted Average Remaining Contractual Life	9 years 4 months 10 days
$ 12.50 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$12.50
Options outstanding	106,200
Options Granted, Weighted Average Remaining Contractual Life	8 years 5 months 16 days
Options exercisable, Range of Exercise Price	$12.50
Options Exercisable	58,509
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 5 months 5 days
$ 12.55 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$12.55
Options outstanding	20,000
Options Granted, Weighted Average Remaining Contractual Life	9 years 4 months 21 days
Options exercisable, Range of Exercise Price	$12.55
Options Exercisable
$ 13.00 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$13
Options outstanding	14,600
Options Granted, Weighted Average Remaining Contractual Life	9 years 6 months 11 days
Options exercisable, Range of Exercise Price	$13
Options Exercisable	3,650
Options Exercisable, Weighted Average Remaining Contractual Life	9 years 6 months 11 days
$ 13.45 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$13.45
Options outstanding	2,000
Options Granted, Weighted Average Remaining Contractual Life	9 years 5 months 23 days
Options exercisable, Range of Exercise Price	$13.45
Options Exercisable
$ 13.50 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$13.50
Options outstanding	14,960
Options Granted, Weighted Average Remaining Contractual Life	9 years 5 months 27 days
Options exercisable, Range of Exercise Price	$13.50
Options Exercisable
$ 13.75 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$13.75
Options outstanding	6,000
Options Granted, Weighted Average Remaining Contractual Life	9 years 8 months 5 days
Options exercisable, Range of Exercise Price	$13.75
Options Exercisable
$ 17.50 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$17.50
Options outstanding	100,000
Options Granted, Weighted Average Remaining Contractual Life	8 years 1 month 10 days
Options exercisable, Range of Exercise Price	$17.50
Options Exercisable	50,000
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 1 month 10 days
$ 22.50 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$22.50
Options outstanding	5,000
Options Granted, Weighted Average Remaining Contractual Life	6 years 7 months 13 days
Options exercisable, Range of Exercise Price	$22.50
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	6 years 7 months 13 days
$ 32.00 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$32
Options outstanding	15,000
Options Granted, Weighted Average Remaining Contractual Life	6 years 6 months 11 days
Options exercisable, Range of Exercise Price	$32
Options Exercisable	15,000
Options Exercisable, Weighted Average Remaining Contractual Life	6 years 6 months 11 days
$ 34.50 [Member]
Summary of option outstanding and exercisable
Options Granted, Range of Exercise Price	$34.50
Options outstanding	5,000
Options Granted, Weighted Average Remaining Contractual Life	6 years 6 months 22 days
Options exercisable, Range of Exercise Price	$34.50
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	6 years 6 months 22 days

Stock_Compensation_Details_3

Stock Compensation (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$1,691	$1,335
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	123	8
Selling, general and administrative expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$1,568	$1,327

Stock_Compensation_Details_4

Stock Compensation (Details 4) (Restricted Stock Issuances [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock Issuances [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Shares	32,450	35,700
Shares granted, Shares	13,200	26,780
Shares vested, Shares	-13,450	-30,030
Shares forfeited, Shares	-10,000
Balance, Shares	22,200	32,450
Beginning Balance, Weighted Average Grant Date Share Price	$14.96	$16.21
Shares granted, Weighted Average Grant Date Share Price	$7.79	$7.39
Shares vested, Weighted Average Grant Date Share Price	$13.86	$9.70
Shares forfeited, Weighted Average Grant Date Share Price	$7
Balance, Weighted Average Grant Date Share Price	$14.95	$14.96

Stock_Compensation_Details_Tex

Stock Compensation (Details Textual) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 18, 2014
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Exercise Price		$13.75
Options outstanding		339,880
Options outstanding, Weighted average remaining contractual life		7 years 7 months 21 days
Warrants/Options granted, Shares Underlying Warrants/Options		6,000
Expected Term		5 years 7 months 17 days
Market price for our common stock		$6.90
Additionally share issued to officer	631,346
Aggregate unrecognized compensation expense of options		$248
Weighted average unvested restricted stock remaining term		1 year 11 months 1 day
Share-based Compensation		1,691	1,335
Weighted Average Grant Date Fair Value		$10.62	$9.47
Director and Consultant [Member] | Minimum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Market price for our common stock		$7.50
Director and Consultant [Member] | Maximum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Market price for our common stock		$14.39
Director, advisory board member and three consultants [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Restricted common stock issued, Shares		13,200
Restricted common stock issued, Value		197	289
Warrants [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Exercise Price		$18.35
Options outstanding		958,185
Weighted average exercise price, per share		$18.35		$50
Warrants/Options granted, Shares Underlying Warrants/Options		958,185
Expected Term		1 year
Price per share		$9.37
Warrants [Member] | Series A January 27, 2014
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Exercise Price		$15
Warrants/Options granted, Shares Underlying Warrants/Options		315,676
Expected Term		3 years
Warrants [Member] | Series B January 27, 2014
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Exercise Price		$45
Warrants/Options granted, Shares Underlying Warrants/Options		157,846
Expected Term		5 years
2012 Equity Incentive Plan [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Exercise Price		$12.50
Options outstanding		30,000
Number of shares vested		119,712
Number of shares non-vested		220,543
Options outstanding, Weighted average remaining contractual life		8 years 10 months 28 days
Weighted average exercise price, per share		$0.23
Common stock reserved for issuance		212,920			550,000
Warrants/Options granted, Shares Underlying Warrants/Options		5,000
Aggregate unrecognized compensation expense of options		1,092
2012 Equity Incentive Plan [Member] | Minimum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Exercise Price		$8.60
Vesting terms range		0 years
2012 Equity Incentive Plan [Member] | Maximum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Exercise Price		$13.50
Vesting terms range		3 years 6 months
Stock Options [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Exercise Price		$11.83	$14.58
Options outstanding		367,080	232,320	30,160
Number of shares vested		166,562
Number of shares non-vested		200,518
Options outstanding, Weighted average remaining contractual life		8 years 6 months	8 years 11 months 23 days
Weighted average exercise price, per share		$14.68	$16.14	$26.58
Weighted average remaining contractual life		8 years 1 month 6 days
Warrants/Options granted, Shares Underlying Warrants/Options		146,560	202,200
Expected Term			10 years
Aggregate intrinsic value of exercisable options		0	4
Market price for our common stock		$6.90	$7.50
Restricted common stock issued, Shares		30,000
Aggregate unrecognized compensation expense of options		$1,691
Weighted average exercise price		$14.75
Stock Options [Member] | Minimum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Expected Term		5 years 7 months 17 days
Stock Options [Member] | Maximum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Expected Term		10 years

Income_Taxes_Details

Income Taxes (Details ) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income tax expense
Current provision	($748)
Deferred provision
Total tax provision (benefit)	($748)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Income Taxes [Abstract]
Federal net operating losses	$3,997	$3,042
State net operating losses	160	531
Stock options	1,104
Federal tax credit	110
Amortization	508	560
Depreciation	-12	-16
Contributions	13	4
Total gross deferred tax assets/(liabilities)	5,880	4,121
Less valuation allowance	-5,880	-4,121
Net deferred tax assets/(liabilities)

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Statutory federal income tax rate and the effective rate reconciliation
Federal statutory rate, amount	($1,770)	($1,449)
Sale of NJ NOL/credits, amount	-495
Permanent differences, amount	136	50
Research and development, amount	-110
State taxes, amount	1
Stock compensation	-584
Valuation allowance	2,074	1,400
Effective tax rate, amount	($748)

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
U.S. federal income tax rate	34.00%
Valuation allowances	$5,880	$4,121
Federal net operating loss carry-forwards, gross	3,997	3,042
State net operating loss carry-forwards, gross	160	531
Federal tax credit	110
Net operating loss carry-forwards term	P3Y
New Jersey State [Member]
Operating Loss Carryforwards [Line Items]
Valuation allowance operating losses, net	8,890
Unused research and development tax credits	15
Proceeds, net of commissions	750
Valuation allowances	5,900	4,100
Federal net operating loss carry-forwards, gross	11,800	9,100
State net operating loss carry-forwards, gross	$2,700	$8,900
Federal and state net operating loss carry-forwards, Expiration date	31-Dec-27
Federal research and development credits, Expiration date	31-Dec-33

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary of future minimum lease payments under the non-cancelable operating lease
2015	$150
2016	152
2017	181
2018	187
2018	191
Total	$861

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	0 Months Ended	1 Months Ended		3 Months Ended	12 Months Ended		1 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 06, 2014	Nov. 28, 2014	Aug. 01, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Jun. 27, 2011	Jul. 18, 2014
	sqft			sqft	sqft
Commitments and Contingencies (Textual)
Additional premises leased	9,079			14,304	14,304
Payment of rent per month	$9		$5
Term of additional space lease	5 years
Rent expense					75	70
Lease expiration date	31-Dec-19
Extended lease period	From July 31, 2017 through December 31, 2019.
Percentage of matching contribution of employer					100.00%
Description of matching contribution of defined contribution plan					The Company's matching contribution is equal to 100 percent on the first four percent of a participant's compensation which is deferred as an elective deferral.
Matching contribution, amount					26
Product liability insurance					The Company currently maintains products liability insurance of $5 million per-occurrence and a $10 million annual aggregate coverage
Settlement yet to receive from january 2015 through april 2016					100
Settlement received from cenegenics		1,900		300
Prepaid expenses and other current assets				745	745	215
Prepaid inventory purchases				664	664
Sponsorship Agreement [Member]
Commitments and Contingencies (Textual)
Number of additional months thereafter								12 months
Expiration date of agreement								30-Jun-12
Number of warrants issued to purchase common stock								3,000
Shares issued upon conversion of warrants							1,000	2,000
Number of warrants term								2 years
Exercise price of warrants								$50
Trading price of common stock on principal trading market, per share								$100
Exchange for each share of common stock underlying the unexercised portion of the Warrants								$50
Number of warrant expired						3,000
Derivative Liability				150	150
Selling, general and administrative expense						28
Supply Agreement [Member]
Commitments and Contingencies (Textual)
Expiration date of agreement									31-Dec-16
Minimum purchase obligations under the agreement, 2014				293	293
Minimum purchase obligations under the agreement, 2015				2,394	2,394
Minimum purchase obligations under the agreement, 2016				$2,101	$2,101
Renewal term of agreement									May be renewed for additional one-year periods unless terminated by either party by giving ninety days' notice before the expiration of the current term.